Annual Congress of the European Academy of Dermatology and Venereology

Get Perspective on Serious Infections With Biologic Therapies

GOTHENBURG, SWEDEN – For psoriasis patients, all tumor necrosis factor inhibitors are associated with roughly the same risks for serious infection, according to a meta-analysis of data from major randomized clinical trials and their long-term, open-label extensions. [Read More]

Noncompliance With Topical Therapies Hampers Tx Effectiveness

GOTHENBURG, SWEDEN - Compliance with topical dermatologic therapies is worse than most physicians realize, according to a new study. [Read More]

Epiduo Plus Doxycycline Brings Rapid Decrease in P. acnes

GOTHENBURG, SWEDEN – Multimodal therapy with adapalene 0.1% and benzoyl peroxide 2.5% in a fixed-dose combination gel plus oral doxycycline proved safe, effective, and well tolerated for severe acne vulgaris in a large, double-blind, multicenter randomized trial. [Read More]

Interrupting Biologic Therapy for Psoriasis: What to Expect

GOTHENBURG, SWEDEN - Biologic therapies have brought dermatologists an unprecedented ability to control moderate to severe psoriasis. But with these treatment victories have come questions about how treatment interruptions affect long-term response, according to Dr. Richard Langley. [Read More]

Onychomycosis is Best Tackled With Evidence-Based Strategies

GOTHENBURG, SWEDEN – Onychomycosis remains a difficult disorder to treat and cure, even with modern antifungal agents. But the chances of success can be greatly enhanced through application of several proven, evidence-based strategies. [Read More]

Sun Exposure Recommendations to Boost Vitamin D Criticized

GOTHENBURG, SWEDEN – The popular practice of trying to improve serum vitamin D status through controlled sun exposure is a no-win proposition that's unlikely to result in adequate vitamin D levels year-round without compromising skin health, according to Brian L. Diffey, Ph.D. [Read More]

Briakinumab Boosts Quality of Life for Psoriasis Patients

GOTHENBURG, SWEDEN - Psoriasis patients given the investigational interleukin-12/interleukin-23 inhibitor briakinumab had significantly better scores on health-related quality of life measures than did patients given etanercept in a phase III randomized, double-blind clinical trial. [Read More]

Quadrupled Desloratadine Dose More Effective For Urticaria

GOTHENBURG, Sweden - Updosing desloratadine by up to fourfold beyond the standard 5 mg for chronic spontaneous urticaria boosted treatment response with no impact on safety, according to the results of a randomized, double-blind controlled trial. [Read More]

Favorable 3-Year Safety Update for Ustekinumab in Psoriasis

GOTHENBURG, SWEDEN – Long-term risks of malignancies, serious infections, and cardiovascular events in ustekinumab-treated psoriasis patients was found to be what is expected in the general U.S. population, according to a 3-year safety analysis of the major randomized clinical trials of the biologic agent. [Read More]